AEGiS-ACRIA: New Drugs from Old Classes

Important note: Information in this article was accurate in 2006. The state of the art may have changed since the publication date.

New Drugs from Old Classes

AIDS Community Research Initiative of America (ACRIA) - Spring 2006

A number of new drugs from existing classes are being studied. Here's a brief rundown of drugs that have started trials in people:

Nucleoside Analog Reverse Transcriptase Inhibitors (NRTIs):

Amdoxovir (DAPD): Early results from an ongoing Phase II study (in people resistant to other NRTIs) showed only a modest anti-HIV effect after two weeks on the drug.
AVX 754: active in vitro against HIV resistant to other NRTIs. Currently in early Phase II trials.
Racivir (PSI 5004): similar to Emtriva (FTC); active against HIV and hepatitis B virus that is resistant to Epivir (3TC). Currently in Phase II trials.

Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs):

Etravirine (TMC 125): Recent study showed effectiveness in people resistant to Sustiva and Viramune; may be very strong in people who have never taken an NNRTI. Currently in Phase II trials. Taken twice a day.
TMC278 (DAPY): shows in vitro activity against NNRTI-resistant virus; in early development.

Protease Inhibitors (PIs):

Brecanavir (GW 640385): active in vitro against resistant virus. In Phase II trials. Taken with Norvir.
Darunavir (TMC 114): Phase II trial showed drug to be effective in people with multi-drug resistance - may receive FDA approval as early as this summer. Taken twice daily with Norvir (ritonavir).

20060301
CR060303

Copyright © 2006 - AIDS Community Research Initiative of America. Reproduction of this article (other than one copy for personal reference) must be cleared through the Editor, ACRIA Update, 230 West 38th Street, 17th Floor, New York, NY 10018; (212) 924-3934; Fax (212) 924-3936 .

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you.

Always watch for outdated information. This article first appeared in 2006. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2006. ÆGIS. All materials appearing on ÆGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of ÆGIS, or the party credited as the provider of the content.